A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)

Summary

The phase II clinical study is to investigate the safety, tolerability, efficacy and pharmacokinetics of ICP-022. Safety, tolerability evaluation, and anti-tumor effects of ICP-022 in Chinese patients with R/R MZL will be evaluated in approximately 110 subjects. Pharmacokinetics of ICP-022 will be evaluated in approximately 20 subjects.

Timeline

Start

2019-04-01

Primary completion

2023-12-27

Completion

2024-02-06

Drugs

Indications